Lye Mun Tho

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning

Lye Mun Tho, M. Glegg, J R Paterson et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 147 citations

Inverse Planning, Radiation Therapy, Gastrointestinal Oncology +9

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer

Ross Carruthers, Lye Mun Tho, Jennifer R. Brown et al. · Colorectal Disease · 2012 · 136 citations · Full text

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 70 citations · Full text

Met Amplification, Medicine, Pathology +8

INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in <i>MET</i> -Amplified NSCLC and First-Line Osimertinib Resistance

Egbert F. Smit, Christophe Dooms, Jo Raskin et al. · Future Oncology · 2021 · 52 citations · Full text